Jump to Main Content
Fc fusion as a platform technology: potential for modulating immunogenicity
- Levin, Ditza, Golding, Basil, Strome, Scott E., Sauna, Zuben E.
- Trends in biotechnology 2015 v.33 no.1 pp. 27-34
- antibodies, bioengineering, drugs, half life, immune system, immunogenicity, proteins, therapeutics
- The platform technology of fragment crystallizable (Fc) fusion, in which the Fc region of an antibody is genetically linked to an active protein drug, is among the most successful of a new generation of bioengineering strategies. Immunogenicity is a critical safety concern in the development of any protein therapeutic. While the therapeutic goal of generating Fc-fusion proteins has been to extend half-life, there is a critical mass of literature from immunology indicating that appropriate design of the Fc component has the potential to engage the immune system for product-specific outcomes. In the context of Fc-fusion therapeutics, a review of progress in understanding Fc biology suggests the prospect of engineering products that have an extended half-life and are able to modulate the immune system.